Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Current Deferred Revenue: 2024

Historic Current Deferred Revenue for Gossamer Bio (GOSS) over the last 1 years, with Dec 2024 value amounting to $17.1 million.

  • Gossamer Bio's Current Deferred Revenue rose 18.07% to $24.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.0 million, marking a year-over-year increase of 18.07%. This contributed to the annual value of $17.1 million for FY2024, which is N/A change from last year.
  • According to the latest figures from FY2024, Gossamer Bio's Current Deferred Revenue is $17.1 million.
  • Over the past 5 years, Gossamer Bio's Current Deferred Revenue peaked at $17.1 million during FY2024, and registered a low of $17.1 million during FY2024.
  • Moreover, its 1-year median value for Current Deferred Revenue was $17.1 million (2024), whereas its average is $17.1 million.